Journal of Pharmacology and Experimental Therapeutics 1992-05-01

Pharmacokinetic/pharmacodynamic relationship of the duration of vasodilating action of organic mononitrates in rats.

T B Tzeng, H L Fung

Index: J. Pharmacol. Exp. Ther. 261(2) , 692-700, (1992)

Full Text: HTML

Abstract

Conflicting information existed regarding the relevance of pharmacokinetics in relation to the duration of action of organic nitrates. We examined this question using three geometric isomers of organic mononitrates, L-isoidide mononitrate, isosorbide-2-mononitrate and isosorbide-5-mononitrate, which produce no active metabolites but possess diverse biological half-lives (T1/2). These compounds were given i.v. to rats at doses which were predetermined to produce equal peak effects on pulse pressure. The relationship between percentage change in pulse pressure and plasma mononitrate level could be described by the classical Hill equation, with similar slope but different EC50 values. A duration of action, defined as the time taken for the pulse pressure to change from -30% to -20% from base line, was measured experimentally. Theoretical analysis suggests that a linear relationship should exist between this duration of action and T1/2/slope, and this was indeed observed (r = 0.99, P less than .01, n = 12), affirming the dependency of pulse pressure pharmacodynamics on the pharmacokinetics of organic mononitrates. Pharmacokinetic modeling of the in vivo time-dependent hemodynamic effects further indicated that the blood compartment data were more consistent with a mechanism of mononitrate action that involves metabolic activation to form nitric oxide and cyclic GMP, rather than direct receptor activation. Using this pharmacodynamic model, the in vivo half-lives of nitric oxide and cGMP were estimated to be 1.6 and 2.0 min, respectively.


Related Compounds

Related Articles:

Effects of isosorbide-5-mononitrate and isosorbide-2-mononitrate on isolated dog aorta: vascular relaxation and increase in cyclic GMP.

1991-01-01

[Arch. Int. Pharmacodyn. Ther. 312 , 104-9, (1991)]

[Study of the bioequivalence of a new isosorbide dinitrate tablet formulation compared with the standard preparation].

1997-06-01

[Arzneimittelforschung 47(6) , 719-26, (1997)]

Concentrations of isosorbide dinitrate, isosorbide-2-mononitrate and isosorbide-5-mononitrate in human vascular and muscle tissue under steady-state conditions.

1990-01-01

[Eur. J. Clin. Pharmacol. 38(2) , 145-7, (1990)]

A pharmacokinetic model for isosorbidedinitrate, isosorbide-2-mononitrate, and isosorbide-5-mononitrate.

1990-01-01

[Drug Metab. Dispos. 18(4) , 429-34, (1990)]

Pharmacokinetics of stereomeric 1,4:3,6-dianhydrohexitol mononitrates in rats.

1993-01-01

[Pharm. Res. 10(1) , 22-7, (1993)]

More Articles...